Related Experiment Video

Updated: Apr 22, 2026

Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology
10:02

Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology

Published on: May 28, 2017

29.8K

Advances in recent patent and clinical trial drug development for Alzheimer's disease

Haibin Liu1, Lirong Wang, Weiwei Su

  • 1Department of Pharmaceutical Sciences, Computational Chemical Genomics Screening Center, School of Pharmacy, NIDA Center of Excellence for Computational Drug Abuse Research, Drug Discovery Institute, University of Pittsburgh, Pittsburgh, PA 15260, USA.

Pharmaceutical Patent Analyst
|October 8, 2014
PubMed

Insights

Alzheimer's disease (AD) treatments are limited due to its complex nature. This review examines current clinical trials and patented compounds targeting AD's various mechanisms.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Genetics

Background:

  • Alzheimer's disease (AD) is a progressive neurodegenerative disorder with complex genetic underpinnings.
  • Current therapeutic options for AD are limited, highlighting the need for novel treatment strategies.
  • The pathophysiology of AD involves multiple factors beyond amyloid-beta and tau, including oxidative stress and inflammation.

Purpose of the Study:

  • To review current therapeutic agents for Alzheimer's disease in clinical trials.
  • To document patented candidate compounds under development for AD treatment.
  • To explore the link between understanding key AD targets and developing new therapeutic agents.

Main Methods:

  • Literature review of clinical trials for Alzheimer's disease therapeutics.
  • Analysis of patented compounds targeting Alzheimer's disease mechanisms.
  • Discussion of recent advancements in understanding AD pathophysiology and therapeutic targets.

Main Results:

  • Identification of various therapeutic agents currently in clinical trials for AD.
  • Documentation of patented compounds with diverse mechanisms of action for AD.
  • Exploration of the relationship between emerging AD targets and drug development.

Conclusions:

  • The polygenic nature of Alzheimer's disease necessitates a multi-targeted therapeutic approach.
  • Ongoing research and development are crucial for discovering effective treatments for AD.
  • Understanding complex AD mechanisms is key to advancing drug discovery and clinical interventions.

Keywords:
Alzheimer’s diseaseamyloid β (Aβ)patenttautherapeutic agents

More Related Videos

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-145105:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

1.1K
Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein08:27

Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein

Published on: July 29, 2018

13.1K

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.2K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.6K
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
10
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
10
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.7K